In this rapidly changing environment, your choice of CDMO partner is
critical. The right partnership can serve as your key to commercial success, while the
wrong one can lead to costly delays, quality issues and compliance risks. To help you
overcome your OSD challenges and drug product manufacturing challenges and
streamline your journey to commercialization, our experts have developed an eBook to
help you find the right CDMO for your project.
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, explains how capping is measured for mRNA synthesis and how upstream process design shapes downstream purity.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, breaks down the company’s one-pot technology for mRNA synthesis, AMCAP, which won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026.
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.